Novartis dis-invests influenza vaccine business to CSL for 275 Million USD.

Novartis to dis-invest its influenza vaccines business to CSL ltd for USD 275 million.As this transaction requires regulatory approval,it is expected to close in second half of 2015 .Novartis remains committed to influenza business during the transaction period to closing which also includes honoring agreements with customers ,R&D for influenza vaccines and product launches.
          Earlier , in April 22, 2014 ,Novartis reached a definitive agreement with GSK(Glaxosmithkline) to exchange certain assets , building global leadership in key segments and focusing Novartis portfolio.
 And Novartis announced a definitive agreement with ELI Lilly and Company to divest its Animal health division further focusing its portfolio on leading business of innovative pharmaceuticals , eye care and generics. 

Gilenya( Fingolimod) out standing data to be shown by Novartis at ACTIMS- ECTRIMS

Gilenya (Fingolimod) used in treatment of multiple sclerosis data to be shown by Novartis at ACTRIMS-ECTRIMS  meeting in Boston , USA from September 10 to 13 , on how Novartis is redefining Multiple sclerosis  treatment goals for patients
      According to Novartis, new data to be presented will reinforce the clinical relevance of brain shrinkage (loss in Brain volume ) and highlight the benefit of including it as 4th key measure of Multiple sclerosis in definition of NEDA. and also other analyses will show that patients who have been treated with Gilenya (Fingolimod) were most likely to achieve NEDA based on assessment of these 4 key measures including shrinkage in brain volume than those on placebo.
        Gilenya (finglolimod)   local and diffuse CNS damage . It prevents cells that cause local inflammation from reaching the brain and also enters CNS(central nervous system) and  reduces diffuse damage.